

DNMT3A Isoform 2 (E1Y5O) Rabbit mAb



Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP, IF-IC	H	Endogenous	95	Rabbit IgG	#Q9Y6K1-2	1788

Product Usage Information

Application

Western Blotting
Immunoprecipitation
Immunofluorescence (Immunocytochemistry)

Dilution

1:1000
1:50
1:400 - 1:1600

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. *Do not aliquot the antibody.*

Specificity/Sensitivity

DNMT3A Isoform 2 (E1Y5O) Rabbit mAb recognizes endogenous levels of total DNMT3A isoform 2 (DNMT3A2) protein. This antibody does not cross-react with other isoforms of DNMT3A or other DNMT proteins, including DNMT1 and DNMT3B.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human DNMT3A isoform 2 (DNMT3A2) protein.

Background

Methylation of DNA at cytosine residues in mammalian cells is a heritable, epigenetic modification that is critical for proper regulation of gene expression, genomic imprinting and development (1,2). Three families of mammalian DNA methyltransferases have been identified: DNMT1, DNMT2, and DNMT3 (1,2). DNMT1 is constitutively expressed in proliferating cells and functions as a maintenance methyltransferase, transferring proper methylation patterns to newly synthesized DNA during replication. DNMT3A and DNMT3B are strongly expressed in embryonic stem cells with reduced expression in adult somatic tissues. DNMT3A and DNMT3B function as *de novo* methyltransferases that methylate previously unmethylated regions of DNA. DNMT2 is expressed at low levels in adult somatic tissues and its inactivation affects neither *de novo* nor maintenance DNA methylation. DNMT1, DNMT3A, and DNMT3B together form a protein complex that interacts with histone deacetylases (HDAC1, HDAC2, Sin3A), transcriptional repressor proteins (RB, TAZ-1), and heterochromatin proteins (HP1, SUV39H1) to maintain proper levels of DNA methylation and facilitate gene silencing (3-8). Improper DNA methylation contributes to diseased states such as cancer (1,2). Hypermethylation of promoter CpG islands within tumor suppressor genes correlates with gene silencing and the development of cancer. In addition, hypomethylation of bulk genomic DNA correlates with and may contribute to the onset of cancer. DNMT1, DNMT3A, and DNMT3B are overexpressed in many cancers, including acute and chronic myelogenous leukemias, in addition to colon, breast, and stomach carcinomas (9-12). There are at least two protein isoforms expressed from the DNMT3A locus, DNMT3A isoform 1 (DNMT3A1) and DNMT3A isoform 2 (DNMT3A2). DNMT3A2 is expressed from an intronic promoter that is downstream from the DNMT3A1 promoter (13,14). As a result, the N-terminal 223 amino acids found in DNMT3A1 are replaced by a different 24 amino acid found in DNMT3A2. Although they have distinct N-termini, both isoforms contain the PWWP domain required for binding to tri-methylated histone H3 lysine 36 (H3K36me3) and the ADD domain required for histone binding and transcriptional regulation. DNMT3A1 is lowly expressed in most cell and tissue types and is localized to heterochromatic regions. DNMT3A2 expression appears to be developmentally regulated and limited to embryonic stem cells, where it is localized to euchromatic regions of the genome, suggesting distinct functions for DNMT3A1 and DNMT3A2. DNMT3A2 is the predominant isoform responsible for *de novo* DNA methylation in embryonic stem cells. In addition, DNMT3A2 is mutated and/or highly expressed in a number of different cancers, including acute myeloid leukemia (AML), teratocarcinoma, neuroblastoma, and lung, testicular, gastric, and breast cancer (13-17).

Background References

- Hermann, A. et al. (2004) *Cell. Mol. Life Sci.* 61, 2571-87.
- Turek-Plewa, J. and Jagodziński, P.P. (2005) *Cell. Mol. Biol. Lett.* 10, 631-47.
- Kim, G.D. et al. (2002) *EMBO J.* 21, 4183-95.
- Fuks, F. et al. (2001) *EMBO J.* 20, 2536-44.
- Geiman, T.M. et al. (2004) *Biochem. Biophys. Res. Commun.* 318, 544-55.
- Rountree, M.R. et al. (2000) *Nat. Genet.* 25, 269-77.
- Pradhan, S. and Kim, G.D. (2002) *EMBO J.* 21, 779-88.
- Fuks, F. et al. (2003) *Nucleic Acids Res.* 31, 2305-12.

9. Mizuno, S. et al. (2001) *Blood* 97, 1172-9.
 10. Robertson, K.D. et al. (1999) *Nucleic Acids Res.* 27, 2291-8.
 11. Xie, S. et al. (1999) *Gene* 236, 87-95.
 12. Kanai, Y. et al. (2001) *Int. J. Cancer* 91, 205-12.
 13. Gujar, H. et al. (2019) *Genes (Basel)* 10, pii: E172. doi: 10.3390/genes10020172.
 14. Chen, B.F. and Chan, W.Y. (2014) *Epigenetics* 9, 669-77.
 15. Chen, B.F. et al. (2014) *Epigenetics* 9, 119-28.
 16. Gao, J. et al. (2013) *J Exp Clin Cancer Res* 32, 86.
 17. Yu, Z. et al. (2015) *Mol Carcinog* 54, 707-19.
-

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation **IF-IC:** Immunofluorescence (Immunocytochemistry)

Cross-Reactivity Key

H: Human

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Alexa Fluor is a registered trademark of Life Technologies Corporation.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.